2025年8月22日，特一药业(002728.SZ)发布2025年半年度报告。截至2025年8月21日，共有10个机构投 资者披露持有特一药业A股股份，合计持股量达1939.91万股，占特一药业总股本的3.78%。其中，前十 大机构投资者包括香港中央结算有限公司、招商银行股份有限公司-兴全中证800六个月持有期指数增强 型证券投资基金、中信证券股份有限公司、北京中和珍贝科技有限公司、中国农业银行股份有限公司- 兴全沪深300指数增强型证券投资基金(LOF)、万家元贞量化选股股票A、广发鑫和混合A、广发集瑞债 券A、万家颐达A、万家家瑞债券A，前十大机构投资者合计持股比例达3.78%。相较于上一季度，前十 大机构持股比例合计上涨了1.91个百分点。 公募基金方面，本期较上一季度新披露的公募基金共计5个，包括万家元贞量化选股股票A、广发鑫和 混合A、广发集瑞债券A、万家颐达A、万家家瑞债券A。 外资态度来看，本期较上一季度新披露的外资机构有 1 家 ，即香港中央结算有限公司。 ...

Company News - Gree Electric Appliances announced a 2024 annual equity distribution plan, proposing a cash dividend of 20 yuan (including tax) for every 10 shares, totaling 11.17 billion yuan [8][9] - Sinopec plans to repurchase A-shares with a budget of 5 billion to 10 billion yuan and intends to distribute cash dividends of 10.67 billion yuan (including tax) for the first half of 2025 [9] - Feilu Co., Ltd. announced that its controlling shareholder is planning a change in control, leading to a temporary suspension of trading [8][10] - Special reports indicate that various companies, including Te Yi Pharmaceutical and Sany Heavy Industry, have reported significant revenue growth in the first half of the year, with Te Yi achieving a 56.54% increase in revenue [7][8] Industry News - The National Energy Administration reported that the total electricity consumption in July reached 10,226 billion kWh, a year-on-year increase of 8.6% [4] - The State Council approved a development plan for the biopharmaceutical industry in Jiangsu Free Trade Zone, aiming to enhance innovation and competitiveness [4] - The Ministry of Commerce reported a 3.5% increase in China's foreign trade in the first seven months of the year, indicating a steady growth trend despite global challenges [4] - The financial regulatory authority is working on guidelines to enhance health insurance services, aiming to improve the industry's operational capabilities and regulatory environment [5] - The Anhui provincial government released a policy to accelerate the development of general artificial intelligence, targeting significant advancements by 2027 [6]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002728 证券简称：特一药业 公告编号：2025-058 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或者重大 遗漏。 根据中国证券监督管理委员会《上市公司募集资金监管规则》《深圳证券交易所上市公司自律监管指引 第1号——主板上市公司规范运作》以及《深圳证券交易所上市公司自律监管指南第2号——公告格式》 的相关规定，特一药业集团股份有限公司（以下简称"公司"）董事会编制了截至2025年6月30日募集资 金存放、管理与使用情况的专项报告。 一、募集资金基本情况 （一）扣除发行费用后的实际募集资金金额和资金到位时间 1、2017年公开发行可转换公司债券募集资金 经中国证券监督管理委员会证监许可[2017]2004号文《关于核准特一药业集团股份有限公司公开发行可 转换公司债券的批复》核准，本公司向社会公开发行面值总额3.54亿元的可转换公司债券，每张面值 100元，共计354万张，期限6年。公司本次发行可转债募集资金总额为人民币354,000,000.00元，利息为 12,776.67元，扣除承销费用、保荐费人民币 ...

证券代码：002728 证券简称：特一药业 公告编号：2025-056 特一药业集团股份有限公司 关于第六届董事会第三次会议决议的公告 特一药业集团股份有限公司（以下简称"特一药业"或"公司"）第六届董事会第 三次会议于 2025 年 8 月 21 日 10:00 在公司子公司海南海力制药有限公司会议室采用现 场及电子通信方式召开，会议通知于 2025 年 8 月 19 日以电子邮件方式发出，会议应出 席董事 6 名，实际出席 6 名。公司非董事高级管理人员列席了本次会议。会议的召集、 召开符合《公司法》和《公司章程》的相关规定。 二、董事会会议审议情况 会议由董事长许荣煌主持，全体董事经过审议，以现场和电子通信方式进行表决， 通过了如下决议： 公司 2025 年 1-6 月的经营情况及财务状况已经公司相关部门编制完成，具体内容 详见《2025 年半年度报告》，该报告拟于 2025 年 8 月 22 日对外报出。 公司 2025 年半年度财务信息已由公司审计委员会审议并取得了全体委员明确同意 的意见。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、董事 ...

Group 1: Company Performance - In the first half of 2025, the company achieved total revenue of 491 million yuan, representing a year-on-year increase of 56.54% [1] - The net profit attributable to shareholders reached 38.01 million yuan, showing a significant year-on-year growth of 1313.23% [1] - The sales volume of the core product "Te Yi" cough tablets reached 331 million pieces, indicating a steady recovery in sales [1] Group 2: Market Trends - The demand for pharmaceutical products in the domestic market is diversifying due to rising living standards and increasing health awareness among residents [2] - There is a growing demand not only for common disease treatment drugs but also for preventive healthcare, chronic disease management, and innovative drugs [2] - The integration of new technologies such as artificial intelligence and big data with the pharmaceutical industry is expected to drive digital transformation and intelligent upgrades [2] Group 3: Strategic Initiatives - The company is actively engaged in product research and development as well as brand building [3] - The company has invested a total of 172 million yuan in brand development in the first half of the year, which has enhanced the brand's visibility and influence, particularly among younger and online consumer groups [3] - The company's integrated advantage of "raw materials + formulations" is expected to become more prominent against the backdrop of rising raw material prices [3]

Core Insights - The company reported a significant increase in revenue and net profit for the first half of 2025, indicating strong financial performance [2] Financial Performance - The company's operating revenue for the first half of 2025 was approximately 491 million yuan, representing a year-on-year increase of 56.54% [2] - The net profit attributable to shareholders was around 38.01 million yuan, showing a substantial year-on-year increase of 1313.23% [2] - Basic earnings per share reached 0.08 yuan, which is a year-on-year increase of 1500% [2]

每天三分钟公告很轻松 飞鹿股份（300665）：筹划公司控制权变更事项 22日起停牌；中国石化和东贝集团拟回购公司股份； 万泰生物：公司九价HPV疫苗首次获得批签发证明；格林美：公司与蔚蓝锂芯签署战略合作协议；特一 药业和千方科技半年报净利同比增逾10倍…… 今日看点 ▼聚焦一：飞鹿股份：实控人筹划公司控制权变更事项 22日起停牌 公司收到控股股东、实际控制人章卫国通知，章卫国正在筹划公司控制权变更相关事宜，方案涉及股份 协议转让、表决权委托及公司向特定对象发行股份。目前，相关方正在就具体交易方案、协议等相关事 项进行论证和磋商。 经公司向深圳证券交易所申请，公司股票自2025年8月22日（星期五）开市起停牌，预计停牌时间不超 过2个交易日。 ▼聚焦二：中国石化和东贝集团拟回购公司股份 中国石化：公司拟使用不低于5亿元、不超过10亿元的自有资金和回购专项贷款，通过上海证券交易所 系统以集中竞价交易方式回购公司发行的A股股份，回购价格为不超过8.72元/股，本次回购股份的期限 自董事会批准方案之日起不超过3个月，回购的股份将全部注销并减少注册资本。按回购股份价格上限 8.72元/股测算，预计本次回购A股股份数量 ...

Buyback and Shareholder Actions - Sinopec plans to repurchase A-shares with a total fund of no less than RMB 5 billion and no more than RMB 10 billion, potentially reducing its registered capital [1] - Hengbang Mining intends to reduce its stake in the Hong Kong-listed company, WanGuo Gold, by up to 40 million shares, representing approximately 3.69% of WanGuo's total share capital [5] Product Approvals and Market Launches - Wantai Biological's nine-valent HPV vaccine has received the batch release certificate, marking its official market launch and enhancing the company's product lineup [1] - Changchun High-tech's subsidiary has received acceptance for the clinical trial application of GenSci143, a dual-specific antibody drug, which may provide new treatment options for certain tumors [7] Financial Performance - Hongxin Electronics reported a 15.01% increase in revenue to RMB 3.494 billion and a 9.85% rise in net profit to RMB 53.99 million for the first half of 2025 [2] - Sanwei Xinan experienced a net loss of RMB 29.39 million in the first half of 2025, despite a 15.19% increase in revenue to RMB 195 million [3] Corporate Developments - TianTan Bio received a commitment from its controlling shareholder to resolve new competition issues arising from a recent acquisition [4] - Feilu Co. announced a potential change in control, leading to a temporary suspension of its stock trading [8] Investment and Expansion - Jinbei Electric's subsidiary has signed a purchase agreement for a factory in Europe, marking significant progress in establishing its European production base [1] - Shengshi Technology plans to establish a wholly-owned subsidiary to integrate AI and humanoid robot technology with innovative toy products, investing RMB 10 million [6]

北京商报讯（记者 丁宁）8月21日晚间，特一药业（002728）披露2025年半年度报告显示，上半年公司 实现营业收入4.91亿元，同比增长56.54%；归属净利润3800.77万元，同比增长1313.23%。 ...

证券日报网讯 8月21日晚间，特一药业发布2025年半年度报告摘要称，2025年半年度公司实现营业收入 491，142，874.06元，同比增长56.54%；归属于上市公司股东的净利润为38，007，729.88元，同比增 长1313.23%。 （编辑 任世碧） ...